[Demonstration of fibrinolytic split products during administration of hormonal contraceptives].
During intake of four different hormonal contraceptives: Ovosiston (Mestranol 0,08 mg, Chlormadinone acetate 2 mg), Non Ovlon (Ethinylestradiol 0,05 mg, Norethindrone acetate 1 mg), Sequenz-Ovosiston and Deposiston (4th, 11th and 18th cycle day 1 mg Ethinylestradiolsulfonate, 25th cycle day 10 mg Norethindrone acetate) an increase of fibrinolytic split products in contrast to low values of the normal menstrual cycle is to be seen. While the values in the first two thirds of application of drugs undulate in the last third they are high in all four pills tested. It seems to be an interference of fibrinogenolysis by estrogens and secondary fibrinolysis after slight disseminated intravascular clotting by gestagens.
D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans
D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D005338:Fibrin Fibrinogen Degradation Products
Nachweis von fibrinolytischen Spaltprodukten während der Einnahme von hormonalen Kontrazeptiva